Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Frontiers in Oncology|May 28, 2026
Correction: Overcoming limitations of cisplatin therapy by additional treatment with the HSP90 inhibitor onalespibAnja Charlotte Lundgren Mortensen, Tabassom Mohajershojai, Mehran Hariri, et al.Frontiers in Oncology|October 26, 2020
Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor OnalespibAnja Charlotte Lundgren Mortensen, Tabassom Mohajershojai, Mehran Hariri, et al.Cancers|September 9, 2023
Enhanced Therapeutic Effects of 177Lu-DOTA-M5A in Combination with Heat Shock Protein 90 Inhibitor Onalespib in Colorectal Cancer XenograftsTabassom Mohajershojai, Douglas Spangler, Saloni Chopra, et al.Frontiers in Oncology|April 18, 2022
In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal CancerTabassom Mohajershojai, Preeti Jha, Anna Boström, et al.European Journal of Nuclear Medicine and Molecular Imaging|October 12, 2023
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenograftsHanna Berglund, Sara Lundsten Salomonsson, Tabassom Mohajershojai, et al.Journal of Photochemistry and Photobiology. B, Biology|May 1, 2023
Photoactive immunoconjugates for targeted photodynamic therapy of cancerSara R G Fernandes, Tabassom Mohajershojai, Sara Lundsten, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 6, 2025
Preclinical Validation of [177Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human TrialsAnja C L Mortensen, Tabassom Mohajershojai, Amanda Gustafsson, et al.Blood Advances|July 17, 2025
Dual targeting of G9a and DNMTs induces anti-tumour effects in multiple myelomaPatrick William Nylund, Berta Garrido-Zabala, Stefania Iliana Tziola, et al.Pageof 1